OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout

REFERENCES

1. 1.↵
   1. Zhu Y,
   2. Pandya BJ,
   3. Choi HK

   . Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011;63:3136–41.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Schumacher HR,
   2. Taylor W,
   3. Edwards L,
   4. Grainger R,
   5. Schlesinger N,
   6. Dalbeth N,
   7. et al.

   Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342–5.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Taylor WJ,
   2. Singh JA,
   3. Saag KG,
   4. Dalbeth N,
   5. MacDonald PA,
   6. Edwards NL,
   7. et al.

   Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol 2011;38:1467–70.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Dalbeth N,
   2. McQueen FM,
   3. Singh JA,
   4. MacDonald PA,
   5. Edwards NL,
   6. Schumacher HR Jr.,
   7. et al.

   Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol 2011;38:1458–61.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Singh JA,
   2. Taylor WJ,
   3. Simon LS,
   4. Khanna PP,
   5. Stamp LK,
   6. McQueen FM,
   7. et al.

   Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol 2011;38:1452–7.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Singh JA,
   2. Yang S,
   3. Strand V,
   4. Simon L,
   5. Forsythe A,
   6. Hamburger S,
   7. et al.

   Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. Ann Rheum Dis 2011;70:1277–81.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Stamp LK,
   2. Khanna PP,
   3. Dalbeth N,
   4. Boers M,
   5. Maksymowych WP,
   6. Schumacher HR Jr.,
   7. et al.

   Serum urate in chronic gout—will it be the first validated soluble biomarker in rheumatology? J Rheumatol 2011;38:1462–6.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Grainger R,
   2. Taylor WJ,
   3. Dalbeth N,
   4. Perez-Ruiz F,
   5. Singh JA,
   6. Waltrip RW,
   7. et al.

   Progress in measurement instruments for acute and chronic gout studies. J Rheumatol 2009;36:2346–55.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Schumacher HR Jr.,
   2. Taylor W,
   3. Edwards NL,
   4. Grainger R,
   5. Schlesinger N,
   6. Dalbeth N,
   7. et al.

   Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342–5.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Dalbeth N,
    2. Zhong CS,
    3. Grainger R,
    4. Khanna D,
    5. Khanna PP,
    6. Singh JA,
    7. et al.

    Outcome measures in acute gout: a systematic literature review. J Rheumatol 2014;41:558–68.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Taylor WJ,
    2. Redden D,
    3. Dalbeth N,
    4. Schumacher HR,
    5. Edwards L,
    6. Simon LS,
    7. et al.

    Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout. J Rheumatol 2014;41:574–80.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Schumacher HR Jr.,
    2. Boice JA,
    3. Daikh DI,
    4. Mukhopadhyay S,
    5. Malmstrom K,
    6. Ng J,
    7. et al.

    Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002;324:1488–92.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Bellamy N,
    2. Downie WW,
    3. Buchanan WW

    . Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol 1987;24:33–6.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Fries JF,
    2. Krishnan E,
    3. Rose M,
    4. Lingala B,
    5. Bruce B

    . Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory. Arthritis Res Ther 2011;13:R147.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Binkley J,
    2. Stratford P,
    3. Lott S,
    4. Riddle D; and
    5. The North American Orthopaedic Rehabilitation Research Network

    . The Lower Extremity Functional Scale: Scale development, measurement properties, and clinical application. Phys Ther 1999;79:4371–83.

    OpenUrl
16. 16.↵
    1. Rubin BR,
    2. Burton R,
    3. Navarra S,
    4. Antigua J,
    5. Londono J,
    6. Pryhuber KG,
    7. et al.

    Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout. Arthritis Rheum 2004;50:598–606.

    OpenUrlCrossRefPubMed